Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to exert favorable effects on hepatic biomarkers and liver-related conditions, including nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. However, the optimal dosage and duration of GLP-1RA therapy necessary to achieve these extrapancreatic hepatic benefits remain unclear. In this case report, we presented a 28-year-old White Hispanic female with Class I obesity and newly diagnosed type 2 diabetes who demonstrated a marked and rapid normalization of persistently elevated alanine aminotransferase levels following the initiation of subcutaneous semaglutide therapy. This case report highlighted the potential for immediate hepatic improvement with GLP-1RA treatment, exceeding commonly anticipated clinical outcomes in primary care.